Buy Arbidol powder for oral suspension 25mg/5ml 37g in pharmacies
A homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
Treatment: 10 ml x 4 times a day, 5 days Post-exposure prophylaxis: 10 ml x 1 time a day, 10–14 days Seasonal prophylaxis: 10 ml x 2 times a week, 3 weeks
Composition and description
Active substance: 5 ml of suspension contains: umifenovir (umifenovir hydrochloride monohydrate – 25.88 mg), (in terms of umifenovir hydrochloride – 25.00 mg).
Excipients: Sodium chloride – 26.85 mg, maltodextrin (Kleptose Linecaps) – 750.00 mg, sucrose (sugar) – 840.42 mg, colloidal silicon dioxide (Aerosil) – 24, 60 mg, titanium dioxide – 25.00 mg, pregelatinized starch (type PA5PH) – 129.50 mg, sodium benzoate – 9.25 mg, banana flavor – 12.40 mg, cherry flavor – 6.10 mg.
Description: Granular powder of white or almost white color with a characteristic fruity odor.
Description of the prepared suspension: a homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
Release form: Powder for the preparation of suspension for oral administration, 25 mg/5 ml.
37 g in bottles with a capacity of 125 ml (with a mark to the level of 100 ml) of dark (amber) glass.
One bottle, along with instructions for use and a measuring spoon, is placed in a cardboard pack. Contraindications Hypersensitivity to umifenovir or any component of the drug.
Age up to 2 years; age up to 6 years (according to indications, nonspecific prevention of SARS); age up to 12 years (according to indications for treatment of SARS).
Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption. Dosage 5 mg/ml Indications for use Prevention and treatment of influenza A and B, other acute respiratory viral infections in children over 2 years of age and adults; complex therapy of acute intestinal infections of rotavirus etiology in children from 2 years of age; — nonspecific prevention of severe acute respiratory syndrome (SARS) in children over 6 years of age and adults; treatment of severe acute respiratory syndrome (SARS) in children over 12 years of age and adults. Interaction with other drugs When prescribed with other drugs, no negative effects were noted. Overdose Not noted. pharmachologic effect
Pharmacological group: Antiviral agent.
Pharmacodynamics: Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (coronavirus associated with severe acute respiratory syndrome ( SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK) cells.
Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.
Refers to low-toxic drugs (LD50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses. Pharmacokinetics. Quickly absorbed and distributed throughout organs and tissues. The maximum concentration in blood plasma when taking the drug at a dose of 200 mg of umifenovir is achieved after 1 hour, the volume of distribution (Vd) is 1432 l. Metabolized in the liver. The half-life averages 11 hours. About 40% is excreted unchanged, mainly in the bile (38.9%) and, in small quantities, in the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated. Pregnancy and breastfeeding The use of Arbidol® during pregnancy is contraindicated. It is not known whether the active substance of Arbidol® or its metabolites passes into breast milk in women during lactation. If it is necessary to use the drug Arbidol®, you should stop breastfeeding. Conditions for dispensing from pharmacies Without a prescription. Side effects Allergic reactions: rarely (with a frequency of at least 1/10000, but less than 1/1000) - skin itching, rash, angioedema, urticaria; very rarely (with a frequency of less than 1/10,000) - anaphylactic reactions.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor. Special instructions When prescribing to patients with diabetes mellitus, as well as on a low-calorie diet, it is necessary to take into account that the suspension contains sucrose (0.8 g/5 ml or 0.06 XE/5 ml). It is necessary to follow the regimen and duration of taking the drug recommended in the instructions. If you miss taking one dose of the drug, the missed dose should be taken as early as possible and continue the course of taking the drug according to the started regimen.
When calculating the amount of suspension required for a course of administration, it is necessary to take into account the shelf life of the prepared suspension, which is 10 days. A course of treatment for the indication of nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in children from 2 to 6 years of age will require two bottles of the drug Arbidol®. It does not exhibit central neurotropic activity and can be used in medical practice by people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.). Storage conditions Store at a temperature not exceeding 25 C.
Store the prepared suspension at a temperature not exceeding 8 C (in the refrigerator). Do not freeze.
Keep out of the reach of children. Directions for use and dosage: Orally, before meals.
Preparation of the suspension.
Add 30 ml (or approximately 2/3 of the bottle volume) of boiled water and cooled to room temperature to the bottle containing the powder. Close the bottle with a lid, turn it upside down and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to a volume of 100 ml (up to the mark on the bottle) and shake again. Before each dose, shake the contents of the bottle thoroughly until a homogeneous suspension is obtained. Measure a single dose using the included measuring spoon.
Single dose (depending on age): from 2 to 6 years - 10 ml (50 mg) from 6 to 12 years - 20 ml (100 mg) over 12 years and adults - 40 ml (200 mg) Dosage regimens:
Nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in a single dose 2 times a week for 3 weeks.
Nonspecific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections in a single dose once a day for 10-14 days.
Treatment of influenza and other acute respiratory viral infections with an uncomplicated course in a single dose 4 times a day (every 6 hours) for 5 days.
Complex therapy of acute intestinal infections of rotavirus etiology in a single dose 4 times a day (every 6 hours) for 5 days.
For nonspecific prevention and treatment of severe acute respiratory syndrome (SARS):
For nonspecific prevention of SARS (upon contact with a patient) in children from 6 years of age and adults: children from 6 to 12 years of age - 20 ml (100 mg), children over 12 years of age and adults - 40 ml (200 mg) once a day. within 12-14 days.
For the treatment of SARS in children over 12 years of age and adults: children over 12 years of age and adults – 40 ml (200 mg) 2 times a day for 8-10 days.
Arbidol suspension - instructions for use for children
2+ Where to buy
A homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
- Treatment:
10 ml x 4 times a day, 5 days - Post-exposure prophylaxis:
10 ml x 1 time per day, 10–14 days - Seasonal prophylaxis:
10 ml x 2 times a week, 3 weeks
Active substance:
Umifenovir (umifenovir hydrochloride monohydrate – 25.88 mg), (in terms of umifenovir hydrochloride – 25.00 mg).
Trade name of the drug:
Arbidol®
International nonproprietary name:
umifenovir
Dosage form:
powder for the preparation of suspension for oral administration.
Composition per 5 ml
active substance:
umifenovir (umifenovir hydrochloride monohydrate – 25.88 mg), (in terms of umifenovir hydrochloride – 25.00 mg);
excipients:
sodium chloride – 26.85 mg, maltodextrin (Kleptose Linecaps) – 750.00 mg, sucrose (sugar) – 840.42 mg, colloidal silicon dioxide (Aerosil) – 24, 60 mg, titanium dioxide – 25.00 mg, pregelatinized starch (type PA5PH) – 129.50 mg, sodium benzoate – 9.25 mg, banana flavor – 12.40 mg, cherry flavor – 6.10 mg.
Description:
granular powder of white or almost white color with a characteristic fruity odor.
Description of the prepared suspension:
a homogeneous suspension of white or white with a yellowish or creamy tint of color with a characteristic fruity odor.
Pharmacotherapeutic group:
antiviral agent.
ATX Code:
[J05AX13]
Pharmacological properties
Pharmacodynamics
Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses - causative agents of acute respiratory viral infections (ARVI) (coronavirus (Сoronavirus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK) cells.
Therapeutic effectiveness for viral infections is manifested in a decrease in the duration and severity of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with viral infection and exacerbations of chronic bacterial diseases.
In the treatment of influenza or ARVI in adult patients, a clinical study showed that the effect of the drug Arbidol® in adult patients is most pronounced in the acute period of the disease and is manifested by a reduction in the time for resolution of symptoms of the disease, a decrease in the severity of manifestations of the disease and a reduction in the time for elimination of the virus.
Therapy with Arbidol® leads to a higher frequency of relief of symptoms of the disease on the third day of therapy compared to placebo - 60 hours after the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza is more than 5 times higher than the same indicator in the placebo group.
A significant effect of the drug Arbidol® on the rate of elimination of the influenza virus was established, which, in particular, was manifested by a decrease in the frequency of detection of viral RNA on the 4th day. Refers to low-toxic drugs (LD50 > 4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.
Pharmacokinetics
Quickly absorbed and distributed throughout organs and tissues. The maximum concentration in blood plasma when taking the drug at a dose of 200 mg of umifenovir is achieved after 1 hour, the volume of distribution (Vd) is 1432 l. Metabolized in the liver. The half-life averages 11 hours. About 40% is excreted unchanged, mainly in the bile (38.9%) and in small amounts in the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated.
Indications for use
- prevention and treatment of influenza A and B, other acute respiratory viral infections in children over 2 years of age and adults;
- complex therapy of acute intestinal infections of rotavirus etiology in children over 2 years of age.
Contraindications
- Hypersensitivity to umifenovir or any component of the drug.
- Age up to 2 years. First trimester of pregnancy. Breast-feeding.
- Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.
- Carefully
- Second and third trimesters of pregnancy.
- Use during pregnancy and breastfeeding
In animal studies, no harmful effects on pregnancy, embryonic and fetal development, labor or postnatal development were identified. The use of Arbidol® in the first trimester of pregnancy is contraindicated. In the second and third trimester of pregnancy, Arbidol® can only be used for the treatment and prevention of influenza and if the expected benefit to the mother outweighs the potential risk to the fetus. The benefit/risk ratio is determined by the attending physician. It is not known whether Arbidol® passes into breast milk in women during lactation. If it is necessary to use the drug Arbidol®, you should stop breastfeeding.
Directions for use and doses
Inside, before meals.
Preparation of the suspension.
Add 30 ml (or approximately 2/3 of the bottle volume) of boiled water and cooled to room temperature to the bottle containing the powder. Close the bottle with a lid, turn it upside down and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to a volume of 100 ml (up to the mark on the bottle) and shake again. Before each dose, shake the contents of the bottle thoroughly until a homogeneous suspension is obtained. Measure a single dose using the included measuring spoon.
Single dose of the drug (depending on age):
| Age | Single dose, ml suspension (mg umifenovir) |
| from 2 to 6 years | 10 ml (50 mg) |
| from 6 to 12 years | 20 ml (100 mg) |
| over 12 years old and adults | 40 ml (200 mg) |
Dosage regimen (depending on age):
| Indication | Dosage regimen |
| In children from 2 years of age and adults: | |
| Nonspecific prevention during an epidemic of influenza and other acute respiratory viral infections | in a single dose 2 times a week for 3 weeks. |
| Nonspecific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections | in a single dose 1 time per day for 10-14 days. |
| Treatment of influenza and other acute respiratory viral infections | in a single dose 4 times a day (every 6 hours) for 5 days. |
| In children from 2 years of age: | |
| Complex therapy of acute intestinal infections of rotavirus etiology | in a single dose 4 times a day (every 6 hours) for 5 days. |
Use the drug only according to the indications, method of administration and in the doses indicated in the instructions.
The drug should be taken from the moment the first symptoms of influenza and other acute respiratory viral infections appear, preferably no later than 3 days from the onset of the disease.
If, after using the drug Arbidol® for three days in the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), then you must consult a doctor to assess the validity of taking the drug.
When treating influenza and ARVI, concomitant symptomatic therapy is possible, including taking antipyretic drugs, mucolytics and local vasoconstrictors.
Side effect
The drug Arbidol® is a low-toxic drug and is usually well tolerated.
Side effects are rare, usually mild or moderate and transient.
The frequency of adverse drug reactions is determined in accordance with the WHO classification: very often (with a frequency of more than 1/10), often (with a frequency of at least 1/100, but less than 1/10), infrequently (with a frequency of at least 1/1000, but less than 1/100), rare (with a frequency of at least 1/10,000, but less than 1/1000), very rare (with a frequency of less than 1/10,000), frequency unknown (cannot be determined from the available data).
Immune system disorders: rarely - allergic reactions - itching, rash, angioedema, urticaria; very rarely - anaphylactic reactions.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
Not marked.
Interaction with other drugs
When prescribed with other drugs, no negative effects were noted.
No special clinical studies have been conducted to study the interactions of the drug Arbidol® with other drugs.
There was no evidence of undesirable interactions with antipyretic, mucolytic and local vasoconstrictor drugs in a clinical study.
special instructions
When prescribing to patients with diabetes mellitus, as well as on a low-calorie diet, it is necessary to take into account that the suspension contains sucrose (0.8 g/5 ml or 0.06 XE/5 ml). It is necessary to follow the regimen and duration of taking the drug recommended in the instructions. If you miss taking one dose of the drug, the missed dose should be taken as early as possible and continue the course of taking the drug according to the started regimen.
If, after using the drug Arbidol® for three days in the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), then you must consult a doctor to assess the validity of taking the drug.
When calculating the amount of suspension required for a course of administration, it is necessary to take into account the shelf life of the prepared suspension, which is 10 days. For a course of treatment indicated for nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in children from 2 to 6 years old, two bottles of the drug Arbidol® will be required.
Impact on the ability to drive vehicles and machinery
It does not exhibit central neurotropic activity and can be used in medical practice by people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).
Release form
Powder for the preparation of suspension for oral administration, 25 mg/5 ml. 37 g in bottles with a capacity of 125 ml (with a mark to the level of 100 ml) of dark (amber) glass. One bottle, along with instructions for use and a measuring spoon, is placed in a cardboard pack.
Storage conditions
Store at a temperature not exceeding 25 °C. Store the prepared suspension at a temperature not exceeding 8 °C (in the refrigerator). Do not freeze. Keep out of the reach of children.
Best before date
Powder for the preparation of a suspension for oral administration – 2 years. Prepared suspension – no more than 10 days. Do not use after the expiration date stated on the package.
Vacation conditions
Available without a prescription.
Marketing authorization holder/organization receiving consumer complaints
PJSC OTCPharm, Russia
123317, Moscow, st. Testovskaya, 10 Tel. Fax
305022, Russia, Kursk, st. 2nd Aggregatnaya, 1a/18 tel./fax
Is Arbidol suitable for breastfeeding women?
Arbidol is a low-toxic medicine. When using it, side effects are extremely rarely observed. Unfortunately, no experiments have been conducted regarding the effect of the drug on breastfeeding. The instructions note that it is unknown how much of the substance passes into breast milk. Therefore, it is more advisable to interrupt breastfeeding during treatment.
But still, some doctors prescribe the drug during lactation, until a negative effect on the child has been recorded.
Indications for use
Most often, doctors recommend using Arbidol for the prevention and treatment of viral diseases.
The medicine is recommended for:
- influenza type A and B
- acute respiratory viral infection
- bronchitis, pneumonia (complex therapy)
- immunodeficiency
- severe acute respiratory disease
In addition, the medication is prescribed for:
- prevention of infectious diseases after surgery
- normalization of immunity
Doctors prescribe the drug to children under 3 years of age for intestinal infections of rotavirus etiology (complex treatment).
What kind of medicine is Arbidol?
The drug Arbidol is a fairly effective antiviral agent.
The medication specifically affects viruses and provokes the production of interferon in the human body.
The active component of Arbidol helps stimulate the cellular, humoral reactions of the immune system, thereby increasing resistance to viral pathologies.
Due to the mechanism of action on the body, the medicine can be called a fusion inhibitor. Taking a pharmaceutical product helps:
- reducing the incidence of complications associated with exposure to viruses
- reduces the risk of exacerbation of chronic bacterial diseases
What is stronger Arbidol or Anaferon
The homeopathic remedy Anaferon is prescribed for colds; it is also suitable for strengthening the immune system. However, the drug does not have an antiviral effect. When treating pathologies, its use is effective only in the initial stages of the disease.
The drug Arbidol perfectly fights viruses, so in case of viral diseases it is better to opt for it, it is more effective.
Both medications are recommended to be taken together with other medications if a person suffers from a serious illness. But Anaferon and Arbidol are excellent for use for preventive purposes, as they do not harm the body.
Before starting to take Arbidol, it is recommended that you carefully read the instructions included with the drug.
